Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · IEX Real-Time Price · USD
2.880
+0.030 (1.05%)
At close: May 31, 2024, 4:00 PM
2.990
+0.110 (3.82%)
After-hours: May 31, 2024, 7:42 PM EDT
Caribou Biosciences Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Caribou Biosciences stock have an average target of 20.67, with a low estimate of 19 and a high estimate of 24. The average target predicts an increase of 617.71% from the current stock price of 2.88.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CRBU stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 2 | 2 | 2 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 5 | 5 | 4 | 4 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Truist Securities | Truist Securities | Strong Buy Maintains $19 | Strong Buy | Maintains | $19 | +559.72% | May 16, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $24 | Strong Buy | Reiterates | $24 | +733.33% | May 13, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $23 → $24 | Strong Buy | Maintains | $23 → $24 | +733.33% | Mar 19, 2024 |
RBC Capital | RBC Capital | Buy Reiterates $19 | Buy | Reiterates | $19 | +559.72% | Mar 12, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Nov 8, 2023 |
Financial Forecast
Revenue This Year
11.98M
from 34.48M
Decreased by -65.26%
Revenue Next Year
12.88M
from 11.98M
Increased by 7.53%
EPS This Year
-1.88
from -1.38
EPS Next Year
-2.13
from -1.88
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 19.3M | 24.5M | 223.3M | 111.3M | 851.0M |
Avg | 12.0M | 12.9M | 76.6M | 78.7M | 363.9M |
Low | 2.4M | n/a | 9.8M | 17.3M | 193.1M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -44.0% | 104.2% | 1,633.5% | 45.4% | 980.9% |
Avg | -65.3% | 7.5% | 494.4% | 2.9% | 362.2% |
Low | -93.2% | - | -23.9% | -77.4% | 145.2% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -1.68 | -1.55 | -0.70 | -3.96 | -0.76 |
Avg | -1.88 | -2.13 | -1.99 | -3.85 | -0.73 |
Low | -1.96 | -2.95 | -2.82 | -3.69 | -0.71 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.